Literature DB >> 17914087

Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.

Ta-Chun Yuan1, Suresh Veeramani, Ming-Fong Lin.   

Abstract

Neuroendocrine (NE) cells represent a minor cell population in the epithelial compartment of normal prostate glands and may play a role in regulating the growth and differentiation of normal prostate epithelia. In prostate tumor lesions, the population of NE-like cells, i.e., cells exhibiting NE phenotypes and expressing NE markers, is increased that correlates with tumor progression, poor prognosis, and the androgen-independent state. However, the origin of those NE-like cells in prostate cancer (PCa) lesions and the underlying molecular mechanism of enrichment remain an enigma. In this review, we focus on discussing the distinction between NE-like PCa and normal NE cells, the potential origin of NE-like PCa cells, and in vitro and in vivo studies related to the molecular mechanism of NE transdifferentiation of PCa cells. The data together suggest that PCa cells undergo a transdifferentiation process to become NE-like cells, which acquire the NE phenotype and express NE markers. Thus, we propose that those NE-like cells in PCa lesions were originated from cancerous epithelial cells, but not from normal NE cells, and should be defined as 'NE-like PCa cells'. We further describe the biochemical properties of newly established, stable NE-like lymph node carcinoma of the prostate (LNCaP) cell lines, transdifferentiated from androgen-sensitive LNCaP cells under androgen-deprived conditions. Knowledge of understanding NE-like PCa cells will help us to explore new therapeutic strategies for treating PCa.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914087     DOI: 10.1677/ERC-07-0061

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  95 in total

1.  Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.

Authors:  Chunxiao Wu; Alexander W Wyatt; Anna V Lapuk; Andrew McPherson; Brian J McConeghy; Robert H Bell; Shawn Anderson; Anne Haegert; Sonal Brahmbhatt; Robert Shukin; Fan Mo; Estelle Li; Ladan Fazli; Antonio Hurtado-Coll; Edward C Jones; Yaron S Butterfield; Faraz Hach; Fereydoun Hormozdiari; Iman Hajirasouliha; Paul C Boutros; Robert G Bristow; Steven Jm Jones; Martin Hirst; Marco A Marra; Christopher A Maher; Arul M Chinnaiyan; S Cenk Sahinalp; Martin E Gleave; Stanislav V Volik; Colin C Collins
Journal:  J Pathol       Date:  2012-03-21       Impact factor: 7.996

2.  Targeting CREB for cancer therapy: friend or foe.

Authors:  Xiangshu Xiao; Bingbing X Li; Bryan Mitton; Alan Ikeda; Kathleen M Sakamoto
Journal:  Curr Cancer Drug Targets       Date:  2010-06       Impact factor: 3.428

3.  PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.

Authors:  Laurent Lessard; David P Labbé; Geneviève Deblois; Louis R Bégin; Serge Hardy; Anne-Marie Mes-Masson; Fred Saad; Lloyd C Trotman; Vincent Giguère; Michel L Tremblay
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

4.  Androgen receptor signaling regulates T-type Ca2+ channel expression and neuroendocrine differentiation in prostate cancer cells.

Authors:  Megan Hall; Bryan Todd; Edwin D Allen; Nga Nguyen; Yoon-Jung Kwon; Vu Nguyen; Jennifer L Hearne; Miguel Martin-Caraballo
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

5.  Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.

Authors:  Xuehong Deng; Han Liu; Jiaoti Huang; Liang Cheng; Evan T Keller; Sarah J Parsons; Chang-Deng Hu
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

6.  Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

Authors:  Guillaume Ploussard; Stéphane Terry; Pascale Maillé; Yves Allory; Nanor Sirab; Laurence Kheuang; Pascale Soyeux; Nathalie Nicolaiew; Estelle Coppolani; Bernard Paule; Laurent Salomon; Stéphane Culine; Ralph Buttyan; Francis Vacherot; Alexandre de la Taille
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

Review 7.  Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.

Authors:  Stefano La Rosa; Fausto Sessa; Silvia Uccella
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

8.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Authors:  Z Mounir; F Lin; V G Lin; J M Korn; Y Yu; R Valdez; O H Aina; G Buchwalter; A B Jaffe; M Korpal; P Zhu; M Brown; R D Cardiff; J L Rocnik; Y Yang; R Pagliarini
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

9.  Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.

Authors:  Paula Sotomayor; Alejandro Godoy; Gary J Smith; Wendy J Huss
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

10.  Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.

Authors:  Audrey Dayon; Leyre Brizuela; Claire Martin; Catherine Mazerolles; Nelly Pirot; Nicolas Doumerc; Leonor Nogueira; Muriel Golzio; Justin Teissié; Guy Serre; Pascal Rischmann; Bernard Malavaud; Olivier Cuvillier
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.